[December 18, 2014] |
|
Research and Markets: Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2014
Research and Markets (http://www.researchandmarkets.com/research/mqcxzk/chronic)
has announced the addition of the "Chronic
Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2014" report
to their offering.
This report provides comprehensive information on the therapeutic
development for Chronic Lymphocytic Leukemia (CLL), complete with
comparative analysis at various stages, therapeutics assessment by drug
target, mechanism of action (MoA), route of administration (RoA) and
molecule type, along with latest updates, and featured news and press
releases. It also reviews key players involved in the therapeutic
development for Chronic Lymphocytic Leukemia (CLL) and special features
on late-stage and discontinued projects.
Reasons to buy
-
Provides strategically significant competitor information, analysis,
and insights to formulate effective R&D development strategies
-
Identify emerging players with potentially strong productportfolio
and create effective counter-strategies to gain competitive advantage
-
Develop strategic initiatives by understanding the focus areas of
leading companies
-
Identify and understand important and diverse types of therapeutics
under development for Chronic Lymphocytic Leukemia (CLL)
-
Plan mergers and acquisitions effectively by identifying key players
of the most promising pipeline
-
Devise corrective measures for pipeline projects by understanding
Chronic Lymphocytic Leukemia (CLL) pipeline depth and focus of
Indication therapeutics
-
Develop and design in-licensing and out-licensing strategies by
identifying prospective partners with the most attractive projects to
enhance and expand business potential and scope
-
Modify the therapeutic portfolio by identifying discontinued projects
and understanding the factors that drove them from pipeline
Companies Mentioned:
-
Bristol-Myers Squibb Company
-
F. Hoffmann-La Roche Ltd.
-
Amgen Inc.
-
Sanofi
-
Eli Lilly and Company
-
Viralytics Ltd.
-
Genentech, Inc.
-
MedImmune, LLC
-
Gilead Sciences, Inc.
-
Daiichi Sankyo Company, Limited
-
Emergent BioSolutions Inc.
-
Lentigen Corporation
-
Amorfix Life Sciences Ltd.
-
Piramal Enterprises Limited
-
Celltrion, Inc.
-
Astellas Pharma Inc.
-
BioMarin Pharmaceutical Inc.
-
Richter Gedeon Nyrt.
-
Astex Pharmaceuticals, Inc.
-
Genmab A/S
-
Cyclacel Pharmaceuticals Inc.
-
Celgene Corporation
-
Onyx Pharmaceuticals, Inc.
-
Bayer AG
-
Incyte Corporation
-
Merck KGaA
-
4SC AG
-
Celldex Therapeutics, Inc.
-
Immunomedics, Inc.
-
TG Therapeutics, Inc.
For more information visit http://www.researchandmarkets.com/research/mqcxzk/chronic
[ Back To TMCnet.com's Homepage ]
|